With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...

Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...

President Trump’s nominee to run the FDA secured the Senate HELP Committee’s backing. Elsewhere, Sutro cut jobs and a cell ...

SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that ...

Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder ...

Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Pliant Therapeutics in a report issued on Tuesday, March 4th. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the ...

RTE Fair City viewers have all said Damien “deserves better” as he gears up to return to Carrigstown. Tonight, Dean and ...

One drawback of the Upeak Sport Strap, though, is just how easily it picks up debris, such as dust and hair, thanks to the ...

Native handicrafts made from coconut shells and carabao horns, and the “banig” made primarily from tikog, a special reed ...

Idiopathic pulmonary fibrosis is a progressive and life-threatening lung disease but there are ASX companies bringing hope to ...

The Ford Bronco is an American off-roading icon. If you're in the market to make one your very own, check out our list of 10 things to know before buying.

Acelyrin and Pliant Therapeutics, both of which are viewed as takeover targets for Kevin Tang’s Concentra Biosciences, each adopted a “poison pill” on Thursday morning.